Los Angeles, CA, October 27,
2007
IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg
IBAB.BB) and Elekta AB (publ) (Stockholm, Sweden: EKTA.ST),
today announced a global particle therapy collaboration program
to optimize the seamless integration of proton therapy delivery
and information management systems within the radiation oncology
environment. Both companies currently showcase their products at
the 49th Annual Meeting of ASTRO (American Society for
Therapeutic Radiology and Oncology) held in Los Angeles, CA,
USA, from October 28 to November 1, 2007.
The aim of this collaboration program is to offer fully
integrated, open and comprehensive cancer treatment solutions to
the particle therapy market. Both companies have unique
competence in their respective fields of radiation therapy and
have decided to join forces to simplify the integration of the
many components that is necessary in an advanced proton therapy
center. Dynamic coordinated integration of both linear
accelerator and particle therapy environments will have
significant added value for front-line medical institutions
fighting cancer. IBA and Elekta both supply world-leading
technology and share the philosophy of open architecture and
industry standards.
Under this collaboration agreement IBA and Elekta will provide
particle therapy solutions packages to meet specific clinical
requirements. On the Elekta side, this can include an array of
Elekta products and solutions such as the MOSAIQ™ workflow
management and information system (OIS), MOSAIQ Proton Therapy
module, patient immobilization devices, localization systems,
and even the Elekta Synergy® advanced IMRT and IGRT delivery
system. On the IBA side, the agreement includes the
comprehensive Proteus system. More components and solutions may
be added in the future based on customer requirements.
The collaboration will also include joint development of future
integrated solutions that will offer the most added-value to the
world wide proton therapy customers in their daily activities.
Complementing this development agreement, the two companies will
also join forces in the field of Sales and Marketing, offering
optimized commercial solutions to an extended market.
“The IBA proton therapy solution is intrinsically open to
interface with any radiation therapy system. However, as cancer
centers expect the Oncology Information System (OIS) software
and other radiation therapy equipment to operate seamlessly and
intelligently with the proton therapy system, the IBA and Elekta
joint development will make proton therapy system a benchmark of
integration”, said Pierre Mottet, Chief Executive Officer of IBA.
“Radiation therapy is currently undergoing rapid transformation
in many areas. Intensity modulation, image guidance and workflow
enhancing information management systems are today changing the
face of cancer care all over the world. Just as Elekta is the
driving force behind most of these improvements on the linear
accelerator, IBA has demonstrated their dominant leadership in
particle therapy technology and our common customers use our
products with the IBA system with great satisfaction.” said
Tomas Puusepp, President and CEO of Elekta. “Thanks to the fact
that we share the vision of open systems design approach
together with joint informal cooperation in the past, we have
been able to quickly find common ground, both technically and
commercially. Together, IBA and Elekta will be able to offer an
optimal solution for every need at a comprehensive cancer
center,” Puusepp concluded.
About IBA
IBA delivers solutions of exceptional precision in the fields of
cancer diagnosis and therapy. The company also provides
sterilization and ionization solutions to improve the hygiene
and safety of everyday life. IBA is the undisputed world market
leader in Proton Therapy, with more than 50% market share. The
company is present in over 40 sites in North America, Europe and
Asia with 1,300 employees and its products range are present in
over 5,000 hospitals, medical imaging centers and cancer therapy
centers around the world. IBA is listed on the pan-European
stock exchange EURONEXT, is integrated into the Next Economy
market segment, and belongs to the BelMid index. Website:
http://www.iba-worldwide.com.
About Elekta
Elekta is an international medical technology group, providing
oncologists, radiation therapists, neurosurgeons and many other
medical specialists with state of the art tools to fight serious
disease.
Elekta provides advanced clinical solutions, comprehensive
management and information systems as well as services for
improved cancer care and management of brain disorders.
Elekta’s systems and solutions are used in over 4,500 hospitals
around the world. Clinical and information management solutions
include, among others, Leksell Gamma Knife® for non-invasive
treatment of brain disorders, Elekta Axesse™ and Elekta Synergy®
for stereotactic and image guided radiation therapy and
radiosurgery as well as the MOSAIQ™ suite of software for
image-enabled EMR and efficient management of clinical and
patient data.
With over 2,000 employees globally, the corporate headquarter is
located in Stockholm, Sweden and the company is listed on the
Nordic Exchange under the ticker EKTAb. More information about
Elekta can be found at www.elekta.com. |
|
Media Inquiries:
Michelle Lee
PR and Advertising Manager
Tel: +1 770-670-2447
michelle.lee@elekta.com
Global Marketing inquiries: Peter Gaccione
Vice President,
Global Marketing
Tel: +1 770-670-2380
peter.gaccione@elekta.com
Investor inquiries:
Peter Ejemyr
Group VP,
Corporate Communications, Tel: +46 733 611 000
peter.ejemyr@elekta.com
IBA:
Paul-Emmanuel Goethals, Director, Corporate Business Development
& Investor Relations
Tel: +32 10 47 58 16
paul-emmanuel.goethals@
iba-group.com
Link Disclaimer
|
